Skip to main content
. 2016 Dec;70(6):941–951. doi: 10.1016/j.eururo.2016.03.029

Table 1.

Participant characteristics by study and case-control status

Study Case–control status Participants, N Age at blood collection, yr, mean (SD) Date of blood collection, minimum-maximum BMI, kg/m2, mean (SD) Higher education, % Current smokers, % Geometric mean (95% CI)
Folate,
nmol/l
Vitamin B12, pmol/l
ATBC Case 224 60.9 (5.0) 1985–1988 26.4 (3.5) 3.6 100.0 8.6 (8.2–9.0) 344 (328–360)
Control 440 60.7 (4.8) 1985–1988 25.9 (3.6) 5.5 100.0 8.5 (8.2–8.8) 342 (330–355)
CARET Case 389 62.3 (5.7) 1985–1997 28.5 (4.3) 24.3 52.2 15.3 (14.3–16.5) 299 (288–311)
Control 773 62.1 (5.8) 1985–1996 28.3 (4.5) 23.0 52.1 15.5 (14.7–16.3) 307 (298–316)
EPIC Case 1244 60.0 (6.6) 1989–2003 26.8 (3.4) 25.4 20.9 13.8 (13.3–14.3) 332 (324–340)
Control 1341 59.8 (6.6) 1989–2003 26.8 (3.6) 22.6 23.3 12.7 (12.3–13.2) 327 (321–334)
Janus Case 3000 48.7 (8.8) 1981–2002 25.6 (3.0) NA 39.4 14.1 (14.0–14.3) 451 (445–458)
Control 3000 48.6 (8.7) 1981–2002 25.7 (3.1) NA 39.7 13.9 (13.8–14.1) 444 (438–450)
NSHDC Case 560 56.6 (5.2) 1986–2004 26.0 (3.1) 13.4 28.9 5.9 (5.7–6.2) 334 (326–342)
Control 1044 56.5 (5.2) 1986–2004 26.2 (3.5) 13.0 25.1 5.7 (5.5–5.9) 320 (313–328)
ProtecT Case 1458 62.0 (5.1) 2003–2008 26.7 (3.4) NA 14.3 16.5 (15.9–17.0) 301 (295–307)
Control 1506 61.8 (5.1) 2003–2008 26.9 (3.8) NA 12.5 16.9 (16.4–17.5) 295 (289–300)

ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI = body mass index; CARET = Carotene and Retinol Efficacy Trial; CI = confidence interval; EPIC = European Prospective Investigation into Cancer and Nutrition; NA = data not available; NSHDC = Northern Sweden Health and Disease Study cohort; ProtecT = Prostate Testing for Cancer and Treatment Trial; SD = standard deviation.

The numbers of cases and controls are the maximum number for whom folate and vitamin B12 measurements were available.